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Background
31P MRS is an important tool for the measurement of in
vivo energetics via the ratio PCr/ATP. Low signal-to-noise
(31P molar receptivity is 1/14 that of 1H) coupled with
low concentration of high-energy phosphates can result in
high measurement variability. 31P MRS of human heart
often contains signals originating from blood i.e. 2,3DPG
and ATP. Measurement of myocardial PCr/ATP thus
requires subtraction of blood derived ATP signal. The aim
of this work was to improve blood correction by applying
prior knowledge (PK) of molecular spectral parameters to
the 2,3DPG signal. We demonstrate that accurate spectral
fitting of 2,3DPG prevents proliferation of fitting errors
through blood correction, resulting in improved accuracy
of PCr/ATP measurement.
Methods
A review of the literature for spectral information about
2,3DPG was employed to guide changes to the existing
PK for 2,3DPG, Table 1. Sixteen 31 P spectra were simu-
lated in jMRUI, PCr/ATP ratio fixed at 2.00 with 20%
and 40% noise added. Forty eight datasets from 8 HCM,
8 DCM and 8 normal controls were analyzed. The origi-
nal and the new 2,3DPG fitting PKs were applied to the
each simulated and patient dataset.
Results
Simulated Data
In the data with 20% noise, there were no differences in
the mean and standard deviations (SD) of the PCr/ATP
ratios with the original ( 2.02±0.13) and new 2,3 DPG fit
(2.03±0.12, P=0.3). However, with 40% noise, both the
mean and SD of the PCr/ATP ratios using the original
2,3DPG fit, were significantly higher than with using the
new 2,3DPG fit (original fit: PCr/ATP 2.77±0.99; new fit:
PCr/ATP 2.33±0.46, p<0.05). The mean difference of the
measured PCr/ATP ratio and the actual ratio of 2.00 was
0.77±0.99 for the original fit and 0.33±0.46 for the new fit,
P=0.02.
Patient Data
There was no difference in the mean PCr/ATP with the
different PKs (original fit: HCM 1.96±0.53, DCM 1.47
±0.28, normal 2.26±0.32; new fit: HCM 1.80±0.33, DCM
1.51±0.20, normal 2.22±0.28, P>0.1). However, with the
new PK, there was a substantial improvement in the coef-
ficient of variance of the 2,3DPG fit in all groups (original
fit vs. new fit: HCM 24% vs 15% P<0.005; DCM 22% vs
12% P<0.005; normal controls 23% vs 15% P<0.0005,
Figure 1). This translated into a reduction in the SD of the
PCr/ATP measurements in all 3 groups. In HCM and
DCM, based on this pilot data, in order to detect a 10%
change in PCr/ATP with an intervention (a 0.05, power
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Table 1 A summary of the differences between the
original and new prior knowledge for 2, 3 DPG.
PARAMETER OLD PK NEW PK
2 DPG Amplitude estimate estimate Fixed 3 DPGx0.8
Relative Phase FIxed 0 Fixed 0
Line Width estimate 20-100
Frequency Soft constraint 5.01-6.01
Shape Lorentizian Lorentizian
PARAMETER OLD PK NEW PK
3 DPG Amplitude estimate estimate estimate
Relative Phase FIxed 0 FIxed 0
Line Width estimate 2 DPGx1
Frequency Soft constraint 6.02-6.81
Shape Lorentizian Lorentizian
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80%), the number of subjects needed with the new
2,3DPG PK is reduced from 59 to 27 in HCM and 28 to
14 in DCM.
Conclusions
31P MRS is a valuable tool for assessment of myocardial
metabolism.. This work developed an improved fit for
2,3DPG hence minimising propagation of errors to the
final PCr/ATP calculation. The quality of this outcome is
reflected in the power calculations which illustrate an
almost 50% reduction of sample size required to statisti-
cally demonstrate a change in PCr/ATP with an interven-
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Figure 1 Box plot of the distribution of the coefficient of variance
of 2, 3 DPG measurements for normal volunteers, HCM and DCM
cohorts using the original and new 2, 3 DPG fits. Center of box
represents median, with interquartile limits, whiskers extend to the
maximum and minimum ratios.
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